PF 6459988

Drug Profile

PF 6459988

Alternative Names: PF-06459988; PF-6459988

Latest Information Update: 05 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 09 Jan 2015 Pfizer withdrew a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA, prior to enrolment (NCT02297425)
  • 14 Nov 2014 Preclinical trials in Non-small cell lung cancer in USA (PO) before November 2014
  • 14 Nov 2014 Pfizer plans a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT02297425)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top